David Kallend

10.8k total citations · 8 hit papers
99 papers, 7.8k citations indexed

About

David Kallend is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, David Kallend has authored 99 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Surgery, 21 papers in Endocrinology, Diabetes and Metabolism and 18 papers in Economics and Econometrics. Recurrent topics in David Kallend's work include Lipoproteins and Cardiovascular Health (72 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (18 papers) and Cancer, Lipids, and Metabolism (16 papers). David Kallend is often cited by papers focused on Lipoproteins and Cardiovascular Health (72 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (18 papers) and Cancer, Lipids, and Metabolism (16 papers). David Kallend collaborates with scholars based in United States, United Kingdom and Netherlands. David Kallend's co-authors include Lawrence A. Leiter, R. Scott Wright, Peter Wijngaard, John J.P. Kastelein, Kausik K. Ray, Wolfgang Köenig, Frederick J. Raal, Mark Jaros, Gregory G. Schwartz and Markus Abt and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

David Kallend

94 papers receiving 7.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

2012 1.5k citations Gregory G. Schwartz, Markus Abt et al. New England Journal of Medicine profile →
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

2020 980 citations Kausik K. Ray, R. Scott Wright et al. New England Journal of Medicine profile →
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

2017 738 citations Kausik K. Ray, Ulf Landmesser et al. New England Journal of Medicine profile →
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

2016 586 citations Peter Wijngaard, David Kallend et al. New England Journal of Medicine profile →
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

2020 562 citations Frederick J. Raal, David Kallend et al. New England Journal of Medicine profile →
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

2011 377 citations Zahi A. Fayad, Venkatesh Mani et al. profile →
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

2021 159 citations R. Scott Wright, Kausik K. Ray et al. Journal of the American College of Cardiology profile →
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

2022 131 citations Kausik K. Ray, Frederick J. Raal et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Kallend United States	36	5.4k	2.6k	1.8k	1.5k	1.5k	99	7.8k
Dirk Blom South Africa	36	6.3k 1.2×	2.2k 0.9×	2.0k 1.1×	1.6k 1.1×	946 0.6×	159	8.1k
Georgina Buck United Kingdom	24	3.6k 0.7×	1.6k 0.6×	1.4k 0.8×	905 0.6×	1.8k 1.2×	56	10.0k
Scott M. Wasserman United States	54	10.9k 2.0×	2.5k 1.0×	2.7k 1.5×	1.9k 1.3×	1.6k 1.1×	129	14.4k
Robert Pordy United States	29	5.5k 1.0×	1.6k 0.6×	1.8k 1.0×	1.0k 0.7×	442 0.3×	107	6.6k
James H. Revkin United States	18	3.2k 0.6×	2.3k 0.9×	1.2k 0.7×	879 0.6×	572 0.4×	39	4.8k
Jennifer A. White United States	29	3.9k 0.7×	1.6k 0.6×	2.0k 1.1×	626 0.4×	384 0.3×	59	5.6k
Tim Crowe United States	20	5.6k 1.0×	1.9k 0.7×	2.1k 1.2×	994 0.7×	669 0.5×	38	7.3k
C Pollicino Australia	6	3.5k 0.7×	1.6k 0.6×	1.3k 0.8×	852 0.6×	355 0.2×	9	5.1k
T. Sourjina Australia	8	3.6k 0.7×	1.6k 0.6×	1.3k 0.7×	929 0.6×	364 0.2×	9	5.3k
Gisle Langslet Norway	29	4.3k 0.8×	1.4k 0.5×	869 0.5×	707 0.5×	424 0.3×	73	5.1k

Countries citing papers authored by David Kallend

Since Specialization

Citations

This map shows the geographic impact of David Kallend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kallend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kallend more than expected).

Fields of papers citing papers by David Kallend

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Kallend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kallend. The network helps show where David Kallend may publish in the future.

Co-authorship network of co-authors of David Kallend

This figure shows the co-authorship network connecting the top 25 collaborators of David Kallend. A scholar is included among the top collaborators of David Kallend based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Kallend. David Kallend is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Raal, Frederick J., Vimal Mehta, Meral Kayıkçıoğlu, et al.. (2025). Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. The Lancet Diabetes & Endocrinology. 13(3). 178–187. 6 indexed citations

Kallend, David, et al.. (2025). Lerodalcibep and adjudicated cardiovascular events in a pre-defined pooled analysis of three large long term Phase III studies. Atherosclerosis. 407. 119493–119493.

Burgess, Lesley, et al.. (2024). Long term efficacy and safety of lerodalcibep in patients with atherosclerotic cardiovascular disease (liberate-CVD). Atherosclerosis. 395. 118513–118513. 2 indexed citations

Psaltis, Peter J., Scott M. Wright, Frederick J. Raal, et al.. (2023). Inter-Individual Variability in LDL-C Reductions With Inclisiran—Pooled Data From ORION-10 and ORION-11. Heart Lung and Circulation. 32. S291–S291. 1 indexed citations

Colquhoun, David, R. Scott Wright, Kausik K. Ray, et al.. (2023). Efficacy and Safety of Inclisiran According to Age: A Pooled Analysis of Phase III Studies (ORION 9, 10 and 11). Heart Lung and Circulation. 32. S387–S387. 1 indexed citations

McQuillan, B., R. Scott Wright, David Kallend, et al.. (2023). Pooled Safety and Efficacy of Inclisiran in Patients With Statin Intolerance (ORION-10 and ORION-11). Heart Lung and Circulation. 32. S299–S299.

Lehoux, Dario, David Kallend, Peter Wijngaard, Alan Brown, & Brad Zerler. (2023). The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions. Pharmacology Research & Perspectives. 11(2). e01080–e01080. 2 indexed citations

Ray, Kausik K., Frederick J. Raal, David Kallend, et al.. (2022). Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. European Heart Journal. 44(2). 129–138. 131 indexed citations breakdown →

Ray, Kausik K., R. Scott Wright, David Kallend, et al.. (2020). Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine. 382(16). 1507–1519. 980 indexed citations breakdown →

10.

Ray, Kausik K., David Kallend, Wolfgang Köenig, et al.. (2020). 6 MONTHLY INCLISIRAN AND ATHEROGENIC LIPOPROTEIN REDUCTIONS IN ORION-11. Journal of the American College of Cardiology. 75(11). 1853–1853. 4 indexed citations

11.

Landmesser, Ulf, Arash Haghikia, LA Leiter, et al.. (2020). Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers - a pre-specified analysis from ORION-1.. Cardiovascular Research. 16 indexed citations

12.

Ray, Kausik K., Scott Wright, David Kallend, et al.. (2020). INCLISIRAN AND CARDIOVASCULAR OUTCOMES: ANALYSES FROM ORION-11. Journal of the American College of Cardiology. 75(11). 238–238. 3 indexed citations

13.

Leiter, Lawrence A., Hwee Teoh, David Kallend, et al.. (2018). Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status without Worsening Glycemia. Diabetes. 67(Supplement_1). 4 indexed citations

14.

Kempen, H.J.M., Monica Gomaraschi, Sara Simonelli, et al.. (2016). Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients. Atherosclerosis. 255. 17–24. 25 indexed citations

15.

Joshi, Francis R., Markus Abt, Mark Woodward, et al.. (2016). Does Vascular Calcification Accelerate Inflammation?. Journal of the American College of Cardiology. 67(1). 69–78. 43 indexed citations

16.

Kallend, David, et al.. (2014). Abstract 9907: A Single Infusion of MDCO-216 (ApoA-1 Milano/POPC) Induces Marked Changes on the Lipid Profile. Circulation. 130. 3 indexed citations

17.

Comley, Robert A. & David Kallend. (2012). Imaging in the cardiovascular and metabolic disease area. Drug Discovery Today. 18(3-4). 185–192. 5 indexed citations

18.

Ballantyne, Christie M., Michael Miller, Eric J. Niesor, et al.. (2012). Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study. American Heart Journal. 163(3). 515–521.e3. 49 indexed citations

19.

Shepherd, James, Chris J. Packard, Thomas Littlejohn, et al.. (2004). Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy*. Current Medical Research and Opinion. 20(10). 1571–1578. 10 indexed citations

20.

Schuster, Herbert, Philip J. Barter, Steen Stender, et al.. (2004). Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. American Heart Journal. 147(4). 705–712. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact